Analysis & Opinions
February 11, 2013
Galena Biopharma: Clinical Programs Remain on Track and Valuation is Attractive By Grant Zeng, CFA Balance Sheet ...
January 02, 2013
Aeterna Zentaris Inc. (AEZS) recently announced that its oncology candidate, AEZS-108 (doxorubicin peptide ...
December 10, 2012
Galena On Track to Advance NeuVax By Grant Zeng, CFA Final Results of NeuVax Phase I/II Trials Presented at ...